Purity assay versus content assay: two different numbers

On the subject in the title: Purity assay versus content assay: two different numbers Working notes rather than a conclusion.

I would like to understand what this number means before I repeat it anywhere.

A VendorInvestigate report on a semaglutide lot gives 97.2% purity. The supplier certificate for the same lot states 97.6%. Both documents name a reversed-phase method; neither states the same gradient.

My question is not "who is right". It is: given that those two figures were produced by different methods, what is the largest difference I should expect from method alone, and at what point does a gap stop being explainable that way?

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

When method identifiers are missing: "reversed-phase HPLC" is less specific than "reversed-phase HPLC at 214 nm on a C18 column with a 10 to 40% acetonitrile gradient over 20 minutes". The second lets someone reproduce the analysis. The first does not.

Worth separating two things that the opening post runs together.

Reading old certificates: if a certificate is dated years ago, the lot it describes might be old. That is not automatically a problem but it is worth noting. Fresh testing on the current lot is stronger than old testing on an older lot.

Picking up post #2: that is the part I would want checked first.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

Sterility testing is separate: chromatographic purity, mass spectrometry, and endotoxin testing all say nothing about whether a solution is sterile. If sterility matters, it needs to be tested and reported.

Endotoxin testing is separate: a certificate of purity says nothing about endotoxin. A chemically pure preparation can carry a clinically significant endotoxin load. If endotoxin matters, it needs to be tested and reported.

Amino acid analysis gives content: it hydrolyses the peptide and quantifies the residues. It measures the peptide content independent of chromatographic purity. Very few supplier certificates report it.

This follows post #6 rather than contradicting it.

Counter-ion form is crucial: peptides are isolated as salts, most often trifluoroacetate from reversed-phase purification or acetate after salt exchange. The counter-ion is part of the mass in the vial and is not part of the peptide. Two vials of the same purity, one as TFA and one as acetate, contain different amounts of peptide per milligram.

I read post #8 twice before replying, because I had assumed the opposite.

Water content (residual moisture) matters: lyophilised peptide is not dry. A few percent water is normal. The difference between a TFA salt and an acetate salt can be several percent. Content calculations need the water content to be accurate.

Purity and content are different measurements: purity tells you what proportion of the detected material is the intended species. Content tells you how much of the intended species is present in the container. A lyophilised vial can be 99% pure and contain considerably less than the label claims because the remainder is water, counter-ion and excipient.